1. Medtech Insight
  2. >>Archive

FDA clears Atrix's Atrisorb FreeFlow GTR (guided tissue regeneration) barrier:

Atrix Laboratories has received US FDA 510(k) clearance to market its Atrisorb FreeFlow guided tissue regeneration (GTR) barrier incorporated with the antibiotic doxycycline. The antibiotic, which inhibits bacterial growth, is released over a period of seven days following surgery, said the Fort Collins, Colorado-based company. An earlier version of Atrisorb without the antibiotic component was cleared for sale in the US four years ago (see Clinica No 699, p19). GTRs are used during periodontal surgery to help regenerate bone and tissues destroyed by periodontal disease.

Atrix Laboratories has received US FDA 510(k) clearance to market its Atrisorb FreeFlow guided tissue regeneration (GTR) barrier incorporated with the antibiotic doxycycline. The antibiotic, which inhibits bacterial growth, is released over a period of seven days following surgery, said the Fort Collins, Colorado-based company. An earlier version of Atrisorb without the antibiotic component was cleared for sale in the US four years ago (see Clinica No 699, p19). GTRs are used during periodontal surgery to help regenerate bone and tissues destroyed by periodontal disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Mexico’s New Procurement Rules Aim To Increase Healthcare Investment, But May Face Legal Trouble

 
• By Francesca Bruce

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

Newborn Screening Tests Among FDA Classifications

 
• By Elizabeth Orr

The US FDA has announced classifications for five device types, including four diagnostics as well as a hand cream to protect healthcare workers exposed to radiation. Two of the products are newborn screening tests.

Will Kennedy And Makary Come To Terms On User Fees During Next Round Of MDUFA Negotiations?

 
• By Brian Bossetta

It’s no secret that Marty Makary and Robert F. Kennedy Jr. have a different take on user fees, with Makary viewing them as a funding necessity and Kennedy as a corrupting influence. But will they find a way to strike a balance during the next MDUFA reauthorization talks so each can claim victory?